

DR. RAHUL ROY CHOWDHURY

Consultant - Gynaecological Oncology Specialist

Qualification

MBBS | MRCOG (London) | FRCOG (UK)

Overview

Dr. Rahul Roy Chowdhury is a well-experienced consultant in Gynaecology and Gynaecological Oncology practising at Manipal Hospitals, Mukundapur, Kolkata. With 33 years of extensive experience, including 19 years as a specialist, Dr. Roy Chowdhury is widely renowned for his exceptional expertise in the field of Gynaecological Oncology. He earned his MBBS from the University of Calcutta. He then practised Medicine in the United Kingdom, spending a significant portion of his professional career there, and underwent rigorous training across several prestigious hospitals, ultimately earning the esteemed FRCOG qualification from the Royal College of Obstetricians and Gynaecologists in London. Additionally, he also holds a Certificate of Completion of Training (CCT) from the Professional Medical Educational and Training Board in the UK. He is also a member of the Royal College of Obstetricians and Gynaecologists (MRCOG). He is the best Gynae Oncologist in Kolkata. He specialised in Gynecological Oncology at the esteemed Oxford Cancer Centre located within the John Radcliffe Hospital. Upon returning to India, he quickly established himself as a prominent doctor in this field. Dr. Chowdhury is widely renowned for his exceptional expertise in performing Gynecologic Oncological Surgeries, such as Pelvic and Upper Abdominal Surgeries, Peritonectomies, and Radical Pelvic Floor Clearances in ovarian and cervical cancers. He is proficient in Laparoscopic Pelvic and Retroperitoneal Nodal Clearances in endometrial cancers, including Sentinel Lymph Node Biopsies and surgeries involving cancer of the vulva. As a clinician scientist, he has participated in sponsored and investigator-initiated trials, contributing to practice-changing research in advanced cervical cancer. In addition to his clinical work, Dr. Roy Chowdhury has been invited to Chittagong Medical College to act as a resource person for training consultants in Gynaecological Oncologic Surgery and conducting multidisciplinary tumour boards. His dedication to education and training further solidifies his reputation as a thought leader and expert in the field. Dr. Roy Chowdhury's commitment to providing personalised, high-quality care, coupled with his extensive experience and advanced training, makes him a leading specialist in Gynaecological Oncology in Kolkata

Fellowship & Membership

- Fellow of the Royal College of Obstetricians and Gynaecologists, UK (FRCOG)
- Member of the Royal College of Obstetricians and Gynaecologists, UK (MRCOG)
- Member of the Association of Gynaecologic Oncology
- Member of the Gynae Cancer InterGroup
- Founding member of the Kolkata Gynecological Oncology Trials and Translational Research Group

Field of Expertise

- Expertise in performing Gynaecologic Oncological Surgeries, such as Pelvic and Upper Abdominal Surgeries, Peritonectomies, and Radical Pelvic Floor Clearances in ovarian and cervical cancers, improving the lives of

these patients.

- Skilled in Minimally Invasive Laparoscopic Procedures such as Laparoscopic Pelvic and Retroperitoneal Nodal Clearances for the treatment of endometrial cancers.
- Experienced in performing Vulvar Cancer surgeries and providing specialised care for patients.

Languages Spoken

- English
- Bengali
- Hindi

Awards & Achievements

- Local Mentor for In-Country IGCS Fellowship, India.
- LMIC representative for the 1st Endometrial Cancer Consensus Conference for Clinical Research (ECCC-CR) on November 2nd and 3rd, 2023, in Seoul, Korea.
- Resource person for training consultants at Chittagong Medical College, Chittagong, Bangladesh [Invited by Medical Education and Health Manpower Development, Directorate General of Medical Education, Dhaka].

Talks & Publications

- Ghosh DD, Chowdhury R R, Dutta R, Mukhopadhyay I, Mukhopadhyay A, Roychoudhury S. In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries. <https://doi.org/10.1016/j.gore.2023.101209>.
- Mandal P, Bhattacharjee B, Sen S, Bhattacharya A, Saha SS, Chowdhury RR, Mondal NR, Chakrabarty B, Chatterjee T, Roy S, Sengupta S. Predominance of genomically defined A lineage of HPV16 over D lineage in Indian patients from eastern India with squamous cell carcinoma of the cervix in association with distinct oncogenic phenotypes. *Transl Oncol.* 2021 Oct 27;15(1):101256. doi: 10.1016/j.tranon.2021.101256. Epub ahead of print. PMID: 34717279; PMCID: PMC8564679.
- Kurtz JE, GebSKI V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M; Gynecologic Cancer InterGroup (GCIg) symptom benefit committee. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIg symptom benefit committee. *Gynecol Oncol.* 2021 May;161(2):502-507. doi: 10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19. PMID: 33612336.
- Mukhopadhyay A, Ghosh T, Bhattacharjee D, Chakraborty D, Gupta , Roychowdhury I, Chatterjee P, Vemekar M, Chowdhury RR, Intermittent PARP Inhibitor Regimen In Ovarian Cancer (IPIROC): Origin and Feasibility Of Implementing A Proof -Of -Concept Exploratory Study.18 October 2023 IGCS Abstracts.